UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average	ge burden
hours per respon	ise 0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer						
Kelly Paul Edward (Last) (First) (Middle)			RELMADA THERAPEUTICS, INC. [RLMD]						ID]	(Check all applicable) _X_Director Officer (give title below) Other (specify below)						
C/O RELMADA THERAPEUTICS, INC., 750 THIRD AVENUE, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 12/11/2018						•	ome	. (g.ve title bete	,	Since (specify of	,		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)						.)	6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person						
NEW YORK,, NY 10016									Form filed by More than One Reporting Person							
(City))	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Execution any	Deemed cution Date, if	, if	3. Transac Code (Instr. 8)	(A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D)	Beneficially Owned Following Reported Transaction(s)		Following	Ownership Form:	V. Nature of Indirect Beneficial	
				(Month/Day/Year)		ar)	Code	V	Amoun	(A) or (D)	Price	(Instr. 3 and 4)		(Ownership (Instr. 4)
Common	Stock		12/11/2018				P		5,000	A	\$ 1.213	388,483			D	
indirectly.	<u> </u>		Table II - I	Derivativ	ve Secur	ritie		cont the f	ained i form dis	n this fo splays a	orm are	not req	uired to re d OMB cor	formation espond unl ntrol numb	ess	C 1474 (9- 02)
1 7711 0		a.m:	`	<u> </u>			rants, op				— <u> </u>		la n :	0.31 1	0.1.0	la sv
Derivative Security (Instr. 3)	2. 3. Transac Conversion Date or Exercise Price of Derivative Security 3. Transac (Month/Di		Execution Da	4. Transaction Code Year) (Instr. 8)		on of I	of	and Expiration Date (Month/Day/Year)		Amo Und Secu	itle and bunt of erlying urities rr. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)	
					Code \	V	(A) (D)	Date Exe	e rcisable	Expiration Date	on Title	Amount or Number of Shares				
Repor	ting O	wners														

Daniel Carron Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Kelly Paul Edward C/O RELMADA THERAPEUTICS, INC. 750 THIRD AVENUE, 9TH FLOOR NEW YORK,, NY 10016	X						

Signatures

/s/ Paul E. Kelly	12/11/2018
Signature of Reporting	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.